Poster Submission Information

Advanced Therapies Week 2024 celebrates innovation from across the global cell and gene therapy industry. We warmly invite poster abstract submissions that focus on;

· Foundational science
· Early-stage explorations
· Real-world clinical studies
· New innovative technology
· Commercialization strategies

Your research is the heartbeat propelling the cell and gene therapy field forward and we want to help you stand out by offering a chance to display your work in our poster presentation zone. Showcase your innovations to the forerunners of the cell and gene therapy realm, discover collaborations with potential partners, and broaden your industry connections.

SUBMIT YOUR ABSTRACT
Poster Submissions Guidance
  • The abstract body cannot exceed 2500 characters, exclusive of the title, author block, images, and tables (note: spaces count as characters)
  • Abstracts must be submitted via the online Abstract Submission System. Abstracts will NOT be accepted by email, mail, or fax
  • Phacilitate may reject poster abstracts that are considered inappropriate for any reason.
  • Abstract submissions do not require registration to Advanced Therapies Europe 2024.
  • Approved poster abstracts require registration to Advanced Therapies Week 2024 (all associated fees are the responsibility of the submitter
  • The submission deadline is Monday, December 11th, 2023
Poster Printing & Display Requirements
  • Posters are required to be formatted and printed in portrait (NOT landscape)
  • Poster dimensions should be no larger than 60 cm wide x 90 cm high (24 inches wide x 36 inches high)
  • Poster Presenters are responsible for printing and transporting their posters to the conference venue
  • There will be no onsite printing services available
  • To display your poster, you will be required to have a valid ticket to Advanced Therapies Week 2024
Submit your poster abstract
Not yet registered for the event?
REGISTER NOW
Why Attend – FAQ
Why do we host the event in January?

We hold the event at the start of the year to help therapeutic developers evaluate the commercial trajectory of cell and gene therapy and provide a forum for meaningful collaboration and actionable change to enhance speed, cost, and access across the coming year. 

Why have we split out our manufacturing content for 2024?

Content is one of the main reasons that people attend the event, and our new agenda format makes it even easier to select the sessions that are relevant to you.

By splitting our manufacturing content we hope to help cell & gene therapeutic developers select the right content and gain access to informed end-to-end solutions for their manufacturing, explore disruptive technology, transformative strategies, and case studies for productive partnerships.  

Why have we included the patient’s voice?

The patient voice is a crucial element of our agendas, we have included more patients for 2024 to help therapeutic developers align on how to unite commercial therapeutics strategies and patient-centric development for effective access and deliver remarkable patient outcomes. 

Ready to register?
Secure your seat today